Ascletis completes enrollment for oral obesity drug study

Ascletis Pharma Inc. has completed enrollment for its U.S. 13-week Phase IIa study evaluating ASC30, an oral GLP-1R agonist for obesity and overweight. The study enrolled all 125 participants in just over one month. Topline data are anticipated in the fourth quarter of 2025.

The trial is assessing two oral formulations of ASC30, a once-daily tablet. ASC30 was discovered in-house by Ascletis and holds patent protection until 2044.